New Pancreatic Cancer Drug an FDA Priority

The FDA has granted Celgene's abraxane priority review as a first-line treatment for advanced pancreatic cancer, a move that shortens the normal review period by four months. In this video, health-care analyst David Williamson discusses what these events mean for investors in Celgene and also for its competitors.

Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 26, 2013, at 1:32 PM, jim1rob wrote:

    My father died of Pancreatic Cancer 10 years ago. He was already Stage 4 when we found out and died the following week. Its a strange disease and can creep up out of no where. Very deadly. Would this drug have helped my father. I seriously doubt it, but I hope it helps others. At least diagnose the disease earlier. If it in fact it can be.

Add your comment.

DocumentId: 2453374, ~/Articles/ArticleHandler.aspx, 7/30/2014 12:19:25 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement